Previous 10 | Next 10 |
Gainers: Sasol (NYSE: SSL ) +88% . More news on: Sasol Limited, Western Asset Mortgage Capital Corporation, Caleres, Inc., Stocks on the move, , Read more ...
Gainers: Immunomedics (NASDAQ: IMMU ) +90% . More news on: Immunomedics, Inc., Akers Biosciences, Inc., Exantas Capital Corp., Stocks on the move, , Read more ...
Millendo Therapeutics (NASDAQ: MLND ) -69% after livoletide flunks study. More news on: Millendo Therapeutics, Inc., Menlo Therapeutics Inc., BP Prudhoe Bay Royalty Trust, Stocks on the move, Read more ...
Menlo Therapeutics (NASDAQ: MNLO ) craters 48% premarket on robust volume in reaction to the results from two Phase 3 clinical trials, MTI-105 and MTI-106 , evaluating serlopitant in prurigo nodularis-associated pruritis (itchy skin). More news on: Menlo Therapeutics Inc.,...
BRIDGEWATER, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today annou...
Menlo Therapeutics' (NASDAQ: MNLO ) wholly owned subsidiary, Foamix Pharmaceuticals (NASDAQ: FOMX ) has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea Foam. More news on: Menlo Therapeutics Inc., Foamix Pharmaceut...
BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today ...
Menlo Therapeutics (NASDAQ: MNLO ) initiated with Overweight rating and $8 (161% upside) price target at Barclays. More news on: Menlo Therapeutics Inc., Molecular Templates, Inc., Passage Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, appointed A...
BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today provi...
News, Short Squeeze, Breakout and More Instantly...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...
BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...